JP2020531495A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531495A5
JP2020531495A5 JP2020510543A JP2020510543A JP2020531495A5 JP 2020531495 A5 JP2020531495 A5 JP 2020531495A5 JP 2020510543 A JP2020510543 A JP 2020510543A JP 2020510543 A JP2020510543 A JP 2020510543A JP 2020531495 A5 JP2020531495 A5 JP 2020531495A5
Authority
JP
Japan
Prior art keywords
compound
onecut2
isomer
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020510543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531495A (ja
JP7293194B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047569 external-priority patent/WO2019040647A1/en
Publication of JP2020531495A publication Critical patent/JP2020531495A/ja
Publication of JP2020531495A5 publication Critical patent/JP2020531495A5/ja
Application granted granted Critical
Publication of JP7293194B2 publication Critical patent/JP7293194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020510543A 2017-08-22 2018-08-22 癌治療のための組成物および方法 Active JP7293194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548879P 2017-08-22 2017-08-22
US62/548,879 2017-08-22
PCT/US2018/047569 WO2019040647A1 (en) 2017-08-22 2018-08-22 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Publications (3)

Publication Number Publication Date
JP2020531495A JP2020531495A (ja) 2020-11-05
JP2020531495A5 true JP2020531495A5 (https=) 2021-10-07
JP7293194B2 JP7293194B2 (ja) 2023-06-19

Family

ID=65440144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020510543A Active JP7293194B2 (ja) 2017-08-22 2018-08-22 癌治療のための組成物および方法

Country Status (8)

Country Link
US (1) US11529338B2 (https=)
EP (1) EP3672582B1 (https=)
JP (1) JP7293194B2 (https=)
CN (1) CN111182894A (https=)
AU (1) AU2018321950A1 (https=)
CA (1) CA3073669A1 (https=)
IL (1) IL272782A (https=)
WO (1) WO2019040647A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer
JP7822940B2 (ja) * 2019-10-07 2026-03-03 ディー.イー.ショウ リサーチ,エルエルシー Kv1.3カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物
PL447378A1 (pl) * 2023-12-29 2025-06-30 Uniwersytet Medyczny W Lublinie Zastosowanie lepidylin w leczeniu nowotworu układu nerwowego.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6048877A (en) * 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents
US6218367B1 (en) 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
EP2245199B1 (en) 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US20140056807A1 (en) 2012-08-23 2014-02-27 Cedars-Sinai Medical Center Large oncosomes in human tumors and in circulation in patients with cancer
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
EP2986326B1 (en) 2013-04-15 2018-09-05 Cedars-Sinai Medical Center Methods for detecting cancer metastasis
US20170051149A1 (en) * 2014-04-29 2017-02-23 Ecole Normale Superieure De Lyon Azoaryls as reversibly modulatable tubulin inhibitors
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
WO2015197909A1 (en) * 2014-06-27 2015-12-30 Fermion Oy Process for the preparation of a crystalline polymorph of 2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (benserazide) hydrochloride
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2019504100A5 (https=)
EP3175853B1 (en) Antineoplastic combinations of neratinib and capecitabine
RU2021103727A (ru) Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
JP2015532295A5 (https=)
JP2020502259A5 (https=)
JP2020531495A5 (https=)
JP2017533922A5 (https=)
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
CN110167915A (zh) 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
RU2017128616A (ru) Комбинированное лекарственное средство
JP2019506392A5 (https=)
JP2018193302A (ja) ペンタアザ大環状環複合体による組み合わせ癌免疫療法
EP3922251B1 (en) Cancer immunotheraphy adjuvant
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies
HK1219879A1 (zh) 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
AU2017283653A1 (en) Porphyrin compounds and compositions useful for treating cancer
JP2021511344A5 (https=)
JP2016523830A5 (https=)
JP2018511642A5 (https=)
EP4230205A1 (en) Antitumor pharmaceutical composition and application thereof
US20260041693A1 (en) Combination therapy of cdk7 inhibitors with other anti-cancer therapies
ES2859679T3 (es) Compuestos, composición y usos de los mismos para tratar el cáncer
JPWO2019165237A5 (https=)
JP2019525924A5 (https=)
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral